NCT03761056View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 29, 2019

Primary Completion Date

October 12, 2023

Study Completion Date

October 12, 2023

Conditions
B-cell Lymphoma
Interventions
BIOLOGICAL

Axicabtagene Ciloleucel

A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

DRUG

Fludarabine

Administered according to package insert

DRUG

Cyclophosphamide

Administered according to package insert

Trial Locations (7)

3000

Peter MacCallum Cancer Centre, Melbourne

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

37232

Vanderbilt University Medical Center, Nashville

75475

Hopital Saint Louis, Paris

77030

The University of Texas MD Anderson Cancer Center, Houston

85234

Banner Health MD Anderson Cancer Center, Gilbert

91010-3012

City of Hope, Duarte

All Listed Sponsors
lead

Kite, A Gilead Company

INDUSTRY

NCT03761056 - Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter